Academic Highlights: New Developments in the Treatment of ADHD.[CME]
J Clin Psychiatry 2006;67(1):148-159
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Click to enlarge page
Introducing the topic, Joseph Biederman, M.D., explained that new developments in the treatment of attention-deficit/hyperactivity disorder (ADHD) include more than useful medications. New developments relate to recent neurobiological research findings, research on comorbid diagnoses, explanations of drug mechanisms of action, nonpharmacologic treatment recommendations, and the role that primary care physicians play in treatment of the disorder.